AARDEX still confirms its leading position in the B2B medication adherence market, closing steadily more new deals with Pharma Companies, Biotech’s, Excellence Centers and Universities, over 30 countries in 2018.
Breaking News
Clinical trial failures: Are we counting the cost of poor adherence?
Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance
Bernard Vrijens
July 19, 2024
